Helsinn licenses Aloxi and Gelclair to Riemser Arzneimittel

Helsinn Healthcare SA, a Swiss pharmaceutical group, has signed a distribution and license agreement for Aloxi (palonosetron HCl) and Gelclair in Germany with domestic medium-sized drugmaker Riemser Arzneimittel AG. Aloxi obtained a centralized registration in Europe in 2005 with an indication for the prevention of acute nausea and vomiting associated with highly-emetogenic cancer chemotherapy, and the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The other agent that is part of the accord is Gelclair, a viscous, concentrated, bioadherent oral gel with a mechanical action, indicated for the management of painful symptoms associated with oral lesions of various etiologies, including oral mucositis, irritation due to oral surgery, traumatic ulcers caused by braces or ill-fitting dentures or diseases.